Pharma Business - June 15, 2021
Gesynta Pharma submits an IND to the FDA
Gesynta Pharma has announced that an IND (Investigational New Drug Application) has been submitted to the U.S. Food & Drug Administration for its oral drug candidate GS-248 in patients with systemic sclerosis. Concurrently, more than half of the patients in the ongoing Phase II study in four countries across Europe have been recruited, states the […]
Clinical Trials - January 27, 2021
Gesynta Pharma initiates Phase II study
Gesynta Pharma has announced that the first patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with systemic sclerosis. Systemic sclerosis is a debilitating autoimmune disease that causes serious damage to the microvasculature. This proof-of-concept study will investigate the safety of GS-248 and its efficacy on Raynaud’s […]
Financing - July 21, 2020
Gesynta raises SEK 190 million
Gesynta Pharma has successfully raised SEK 190 million in one of the largest private biotech placements of the year in the Nordics. The placement was led by European life science fund manager Hadean Ventures, joined by existing investor Industrifonden and private funds. “We believe mPGES-1 is an exciting, first-in-class target in systemic sclerosis and other […]
Clinical Trials - June 19, 2020
Promising results from Gesynta Pharma
Gesynta Pharma reports positive Phase I results with its lead candidate GS-248 for microvascular disease. Results from the completed First-in-Human clinical study with GS-248 for the treatment of microvascular disease have been presented at the EULAR 2020 E-Congress. Following these results, Gesynta now intends to commence a Phase II study in patients with Systemic Sclerosis. […]
Clinical Trials - May 15, 2020
Gesynta Pharma announces positive trial results
Gesynta Pharma has reported positive Phase I results with GS-248 for the treatment of microvascular disease. The Phase I study was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses up to 300 mg and multiple once daily doses up to 180 mg for 10 days in healthy male and female […]
Financing - April 4, 2019
Gesynta Pharma secures EUR 6 million for development programs
The company has completed a financing round to provide funds for early clinical development of its lead candidate, GS-248. A consortium consisting of venture capital investor Industrifonden and a group of private life sciences investors provides financial and strategic support to Gesynta’s development programs and brings the company to its next pivotal milestone, to make […]
